Ginkgo Bioworks’ Enzyme Services selected by Israel’s Ambrosia Bio

Ginkgo Bioworks and Ambrosia Bio, an Israeli foodtech company developing novel bioprocesses for the global sugar replacement industry, announced that Ambrosia Bio will leverage Ginkgo Enzyme Services, including its proprietary chassis organisms, to develop an expression strain for the scalable production of the Ambrosia Bio proprietary enzymes used for the conversion of feedstock into allulose. Allulose is an FDA-approved rare sugar that is found in figs, raisins, wheat, maple syrup, and molasses but occurs naturally only in small amounts. Unlike other currently available sweeteners, allulose has a low caloric value – typically under 10% compared to equivalent amounts of sucrose. Over the past three years of stealth mode development, Ambrosia Bio has developed a bioprocess to convert lower-margin feedstocks into rare sugars and specialized ingredients such as allulose. To further optimize its process, Ambrosia Bio will leverage Ginkgo Enzyme Services, an end-to-end service powered by throughput screening and machine learning-guided protein design, to aid its goal of producing an optimized version of its proprietary enzyme in a productive expression strain.